In a report issued on February 7, David Windley from Jefferies reiterated a Buy rating on Charles River Labs (CRL), with a price target of $150. The company’s shares closed on Friday at $125.43.
According to TipRanks.com, Windley is a top 25 analyst with an average return of 20.4% and a 76.1% success rate. Windley covers the Services sector, focusing on stocks such as Molina Healthcare, Centene Corp, and Cigna Corp.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Charles River Labs with a $136.20 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $139.72 and a one-year low of $98.72. Currently, Charles River Labs has an average volume of 386.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Charles River Laboratories International, Inc. is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions.
